In July 2025, CVS Caremark made a significant formulary change that affected millions of Aetna members: tirzepatide (Zepbound) was removed from the standard national formulary for obesity
Others stop because of side effects, cost, muscle loss, or feeling physically unwell
Plant Physiol 158:340351 Cheng MC, Ko K, Chang WL, Kuo WC, Chen GH, Lin TP (2015) Increased glutathione contributes to stress tolerance and global translational changes in Arabidopsis
The injectable GHK-Cu peptide has some promising science, but its currently not approved for systemic use by the FDA
These results position injectable weight-loss meds like these as some of the most effective non-surgical treatments available today